(Q37841589)

24 August 2017

1 reference

title

New nucleoside analogs for patients with hematological malignancies (English)

1 reference

24 August 2017

1 reference

ChEBI release 2020-05-28

1

Tadeusz Robak

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

Expert Opinion on Investigational Drugs

24 August 2017

published in

1 reference

24 August 2017

volume

20

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

343-359

1 reference

Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Novel purine nucleoside analogues for hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Pharmacological and clinical studies on purine nucleoside analogs--new anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Discovery and development of clofarabine: a nucleoside analogue for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Clofarabine: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Nelarabine: efficacy in the treatment of clinical malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Clofarabine and nelarabine: two new purine nucleoside analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Phase I trial of nelarabine in indolent leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor--BCX-1777.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Purine-less death in Plasmodium falciparum induced by immucillin-H, a transition state analogue of purine nucleoside phosphorylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Forodesine: review of preclinical and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

The effects of forodesine in murine and human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Synthesis of analogs of forodesine HCl, a human purine nucleoside phosphorylase inhibitor-Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Chain termination and inhibition of Saccharomyces cerevisiae poly(A) polymerase by C-8-modified ATP analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Preclinical activity of 8-chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Treatment of experimental colitis in mice with LMP-420, an inhibitor of TNF transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

LMP-420, a small-molecule inhibitor of TNF-alpha, reduces replication of HIV-1 and Mycobacterium tuberculosis in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

5-azacytidine in acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Demethylating agents in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Treatment of acute myelogenous leukemia with outpatient azacitidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Repair of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine-induced DNA single-strand breaks by transcription-coupled nucleotide excision repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Troxacitabine in acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Activity of (-)-2'-deoxy-3'-oxacytidine (BCH-4556) against human tumor colony-forming units.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Metabolism of 4'-thio-beta-D-arabinofuranosylcytosine in CEM cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Polymerization of the triphosphates of AraC, 2',2'-difluorodeoxycytidine (dFdC) and OSI-7836 (T-araC) by human DNA polymerase alpha and DNA primase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Enhancement of the in vivo antitumor activity of clofarabine by 1-beta-D-[4-thio-arabinofuranosyl]-cytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Zebularine: A Novel DNA Methylation Inhibitor that Forms a Covalent Complex with DNA Methyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Preferential response of cancer cells to zebularine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Inhibition of DNA methylation and reactivation of silenced genes by zebularine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Zebularine reactivates silenced E-cadherin but unlike 5-Azacytidine does not induce switching from latent to lytic Epstein-Barr virus infection in Burkitt's lymphoma Akata cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. The magic of its chemistry and biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

Current and emerging therapies for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.554822

10.1517/13543784.2011.554822

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference